| Zhang, Jingsong |
NCT05189457: First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer |
|
|
| Recruiting | 2 | 31 | US | Luteinizing Hormone Releasing Hormone, Leuprolide, Triptorelin, Goserslin, Relugolix, Degarelix, New Hormonal Agent, Abiraterone, Enzalutamide, Docetaxel, Tislelizumab, BGB-A317 | H. Lee Moffitt Cancer Center and Research Institute, BeiGene | Prostate Cancer, Stage IV Prostate Cancer | 01/27 | 01/27 | | |
NCT05526989: Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma |
|
|
| Recruiting | 2 | 25 | US | Dostarlimab, Jemperli, Niraparib, Zejula | H. Lee Moffitt Cancer Center and Research Institute, GlaxoSmithKline | Penile Carcinoma | 10/25 | 10/26 | | |
NCT05751941: Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer |
|
|
| Recruiting | 2 | 26 | US | Abiraterone, Enzalutamide, Xtandi, Apalutamide, Sipuleucel-T, Provenge | H. Lee Moffitt Cancer Center and Research Institute, Dendreon | Prostate Cancer, Metastatic Prostate Cancer | 10/25 | 10/25 | | |
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects |
|
|
| Active, not recruiting | 2 | 70 | US | Olaparib, Lynparza, Abiraterone Acetate, Prednisone | Northwestern University, AstraZeneca, National Cancer Institute (NCI) | Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer | 12/26 | 01/27 | | |
KEYNOTE F73, NCT05369000: Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer |
|
|
| Recruiting | 1/2 | 180 | Europe, US | LAVA-1207, LAVA-1207 plus Pembrolizumab | Lava Therapeutics, Merck Sharp & Dohme LLC | Metastatic Castration Resistant Prostate Cancer | 04/27 | 04/27 | | |
NCT02415621: Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer |
|
|
| Active, not recruiting | 1 | 19 | US | Abiraterone Acetate, Zytiga | H. Lee Moffitt Cancer Center and Research Institute | Prostate Cancer | 08/19 | 12/24 | | |
NCT03511196: Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer |
|
|
| Active, not recruiting | 1 | 17 | US | Adaptive Androgen Deprivation Therapy (ADT), GnRH agonist, Abiraterone, Standard of Care, Zytiga, Prednisone, Glucocorticoid | H. Lee Moffitt Cancer Center and Research Institute | Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer, Adenocarcinoma of the Prostate | 06/22 | 06/24 | | |
NCT06193486: Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC |
|
|
| Recruiting | 1 | 30 | US | MSGV1-PSCA-8T28Z, Fludarabine, Fludara, Cyclophosphamide | H. Lee Moffitt Cancer Center and Research Institute | Metastatic Castration-resistant Prostate Cancer | 01/29 | 12/33 | | |
| Active, not recruiting | 1 | 21 | US | CG0070, Nivolumab | H. Lee Moffitt Cancer Center and Research Institute, CG Oncology, Inc., Richard M. Shulze Family Foundation | Muscle-Invasive Bladder Carcinoma, Bladder Cancer | 03/25 | 03/25 | | |
SIDP, NCT05215457: Severity Index of Diquat Poisoning in Evaluating the Prognosis of Acute Diquat Poisoning |
|
|
| Recruiting | N/A | 100 | RoW | | The First Affiliated Hospital with Nanjing Medical University | Poisoning | 03/23 | 06/23 | | |
| Recruiting | N/A | 366 | RoW | Cardiopulmonary rehabilitation, Usual care | The First Affiliated Hospital with Nanjing Medical University | Critical Illness | 06/25 | 12/25 | | |
NCT04964310: Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study |
|
|
| Recruiting | N/A | 339 | RoW | genetic polymorphism | The First Affiliated Hospital with Nanjing Medical University, University of Colorado, Denver, Beijing Genomics Institute, Nanjing Medical University | Acetaminophen, Drug-Induced Liver Injury, Pharmacogenetics, China | 08/23 | 08/25 | | |
